LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Anand Arvindbhai Patel & PACs LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ashish Rajanibhai Patel Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of SEBI (LODR) Regulations, 2015, we enclosed herewith the copies of published newspaper advertisement with respect to the un-audited financial results of the Company for the quarter and half year ended September 30, 2021. The said advertisement was published : - 1). The Economic Times, Ahmedabad Edition-In English; 2) Jay Hind, Ahmedabad Edition - In Gujarati. LINCOLN PHARMACEUTICALS LTD. - 531633 - Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended On September 30, 2021
Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015, we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Thursday, November 11, 2021, have considered and approved the un-audited financial results (Standalone and Consolidated) of the Company along with the limited review reports for the quarter and half year ended on September 30, 2021. Further, we enclose herewith financial highlights of the Company for the aforesaid quarter. LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Outcome for Outcome Of The Board Meeting
Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015, we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Thursday, November 11, 2021, have considered and approved the un-audited financial results (Standalone and Consolidated) of the Company along with the limited review reports for the quarter and half year ended on September 30, 2021. Further, we enclose herewith financial highlights of the Company for the aforesaid quarter. LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Intimation for Consider And Approve The Un-Audited Financial Results
LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2021 ,inter alia, to consider and approve un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended on September 30, 2021. Lincoln Pharmaceuticals Ltd - 531633 - Minutes Of 27Th Annual General Meeting Of The Company
With reference to above, please find enclosed herewith the minutes of the 27th Annual General Meeting of the Company held at 11:00 A.M. on Thursday, the 30th day of September, 2021 through Video Conferencing ('VC') / Other Audio Visual Means (OAVM) to seek the approval of members of the Company on resolutions set out in the Notice convening the Meeting. LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement Under Regulation 30 Of SEBI (LODR)-Updates
This is in continuation to our letter dated September 16, 2021, September 30, 2021 and October 05, 2021 with respect to sanctioning the scheme of amalgamation of Lincoln Parenteral Limited and Lincoln Pharmaceuticals Limited. Further, we would like to inform you that minority shareholders who were holding 1.42% of the paid-up share capital of Transferor Company approached to the Hon''ble High Court of Gujarat and filed a petition R/Special Civil Application No. 15485 of 2021 and the Hon''ble High Court of Gujarat at its hearing held on October 18, 2021 passed an Oral Order that based on the submission made in SCA, issue notice to the respondents returnable on October 28, 2021 and also ad-interim relief in the nature of stay the operation and implementation of the impugned judgment dated September 14, 2021 passed by the Hon''ble National Company Law Tribunal, Ahmedabad Bench vide its order dated September 14, 2021. Lincoln Pharma gets Australia's TGA certification for Gujarat plant
Eyes Australian market for dermatology, gastro and pain management products